Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
CorMedix is a commercial-stage pharmaceutical company focused on preventing and treating infectious and inflammatory complications in dialysis and other critical care patients. The company's lead product, DefenCath (taurolidine/heparin), is an FDA-approved antimicrobial catheter lock solution for hemodialysis patients, targeting a $500M+ US market for catheter-related bloodstream infection (CRBSI) prevention. With minimal revenue despite FDA approval, the stock trades on commercial launch execution and market penetration expectations.
CorMedix generates revenue by selling DefenCath directly to dialysis centers, hospitals, and through specialty distributors. The 92.7% gross margin reflects low manufacturing costs relative to pricing, typical for specialty pharmaceuticals with limited competition. Pricing power derives from clinical differentiation versus standard heparin locks and the high cost of treating CRBSIs (estimated $25,000-$50,000 per infection). The company must execute on market access, payer reimbursement, and physician adoption to convert the addressable market of 500,000+ US hemodialysis patients into revenue. Current negative operating margins reflect commercial infrastructure buildout costs exceeding nascent product sales.
DefenCath quarterly prescription volume and revenue trajectory - market expects inflection from current minimal sales to $50M+ annual run rate
Payer coverage decisions from major Medicare Advantage plans, commercial insurers, and state Medicaid programs affecting reimbursement access
Clinical data releases or real-world evidence publications demonstrating CRBSI reduction rates versus standard of care
Partnership or licensing deals for ex-US markets (Europe, Asia) that validate commercial potential and provide non-dilutive capital
Cash runway updates and financing needs - company burned approximately $10M per quarter in 2025 based on operating cash flow
Reimbursement risk - CMS and private payers may not provide adequate coverage or reimbursement rates for DefenCath, limiting commercial viability despite FDA approval
Clinical adoption barriers - Dialysis centers operate on thin margins and may resist protocol changes requiring staff training and workflow modifications, even with superior clinical outcomes
Regulatory pathway changes - FDA or international regulators could impose additional post-market surveillance requirements or safety studies that increase costs
Patent expiration risk - Core patents expire in the 2030s, limiting the duration of market exclusivity and pricing power
Entrenched standard of care - Heparin locks are generic, inexpensive, and familiar to clinicians, creating inertia against DefenCath adoption despite clinical superiority
Competitive antimicrobial lock solutions in development by larger pharmaceutical companies with superior commercial infrastructure and market access
Alternative infection prevention technologies (antimicrobial catheters, novel materials) that could obviate the need for lock solutions
Pricing pressure from group purchasing organizations (GPOs) and integrated delivery networks seeking cost containment
Cash burn risk - Negative $10M quarterly operating cash flow with $20M-$30M estimated cash balance (based on 1.94x current ratio and balance sheet structure) suggests 6-9 month runway without additional financing
Dilution risk - Likely need for equity raises or convertible debt to fund operations until breakeven, diluting existing shareholders given the $600M market cap
Working capital constraints - Scaling commercial operations requires inventory buildup, accounts receivable financing, and increased payables, straining the 1.94x current ratio
low - Hemodialysis is a non-discretionary medical necessity for end-stage renal disease patients, making demand highly inelastic to economic conditions. However, commercial launch success depends on hospital/dialysis center capital budgets and willingness to adopt new protocols, which can be modestly affected by healthcare system financial stress during recessions. The 500,000+ US dialysis patient population grows steadily regardless of GDP due to aging demographics and diabetes prevalence.
Rising interest rates negatively impact CorMedix through two channels: (1) Higher discount rates compress the present value of future cash flows, particularly punishing pre-profitable biotech with negative near-term cash flows, and (2) Increased financing costs if the company needs to raise debt or dilutive equity capital to fund operations before reaching breakeven. The 1.94x current ratio and negative $10M quarterly cash burn suggest potential financing needs within 12-18 months. Higher rates also make risk-free alternatives more attractive, reducing speculative capital flows into small-cap biotech.
Minimal direct credit exposure as the business model does not involve lending or credit-intensive operations. However, tighter credit conditions can indirectly affect hospital and dialysis center purchasing budgets, potentially slowing DefenCath adoption. The company's own access to capital markets for financing is credit-sensitive given the 0.40x debt/equity ratio and need for continued funding.
growth - Investors are betting on commercial execution and market penetration of DefenCath, not current profitability or cash generation. The -32.2% one-year return and -45.0% six-month return reflect disappointment with launch velocity, attracting contrarian growth investors who believe the market underestimates adoption potential. High-risk tolerance required given negative cash flows, financing uncertainty, and binary commercial outcomes. Not suitable for value or income investors given lack of profitability, dividends, or tangible asset backing.
high - Small-cap biotech with $600M market cap, minimal revenue, and binary commercial outcomes exhibits extreme volatility. Stock moves sharply on quarterly revenue beats/misses, payer coverage announcements, clinical data, and financing events. The -28.4% three-month return demonstrates recent volatility. Beta likely exceeds 1.5x relative to broader market given sector and size characteristics.
